CLINICAL_TRIALS
trial_result
· 2016-02-23
Clinical Trial Update: A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML [Phase 1]
Summary
A Phase I study of IGN523 in relapsed or refractory acute myeloid leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Igenica Biotherapeutics, Inc. | Conditions: Acute Myelogenous Leukemia, Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED